Risperdal Lawsuit Plaintiffs Accuse Pharma Giant of Leading Doctor, Employee Payoffs

Published on April 14, 2014 by Laurie Villanueva

Text-Size:A A A+

 

Pharmaceutical companies have been bribing doctors to prescribe their antipsychotic medications for years; the results of which may have taken the greatest toll on poor and foster children, according to Risperdal lawsuit allegations.

A recent investigation from the Denver Post indicates that foster children in Colorado were 12 times more likely to take an antipsychotic medication in 2012 than others receiving Medicaid care. That demographic was also at an increased risk for receiving multidrug dosages and prescriptions, with nine out of the ten most frequently-used medications by Medicaid including a psychotropic. For non-foster children, only one medication of this class was included in a list of ten.

The results of a U.S. Food and Drug Administration (FDA) study in 2009 may relate to these findings. According to an advisory committee led by the agency that year, one million American children are prescribed antipsychotics annually, with tens of thousands younger than five years old.

Just how many of those scripts were the result of pharmaceutical company pay-offs, though? A former GlaxoSmithKline sales representative quoted by the Denver Post suggests there may have been several. His whistleblower lawsuit in 2012 concluded in a $3 billion settlement with the federal government after he alleged that the company bribed him with ski trips, spa treatments and other offers in return for his promotion of Paxil. When he turned them down, a GlaxoSmithKline manager said he wasn’t being a “team player,” according to the case.

“The sky was the limit,” said the former Colorado Springs sales representative.

J&J Agree to $2.2 Billion Risperdal Lawsuit Settlement

GlaxoSmithKline isn’t the only company accused of leading doctor and employee pay-offs to further sales of their products, however.  In November 2013, Johnson & Johnson agreed to pay $2.2 billion to resolve claims from the U.S. government that it improperly marketed Risperdal and other drugs for uses not approved by the FDA, and for concealing a side effect alleged in Risperdal gynecomastia claims.

Risperdal is an atypical antipsychotic drug prescribed to treat schizophrenia and bipolar disorder in adults and adolescents.  Its list of approved uses expanded in 2006 to include pediatric cases.

According to the Risperdal settlement, Johnson & Johnson was accused of marketing Risperdal in children before then, as well as promoting it to elderly patients with dementia.

Filing a Risperdal Lawsuit

Contact a Risperdal lawsuit attorney today to find out more about side effects that are allegedly associated with the medication, and whether you may be eligible to file a case. Call us now at .